Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Dr. Khan is a Principal Investigator/Supervisory Microbiologist in the Division of Viral Products, Office of Vaccines Research and Review in the Center for Biologics Evaluation and Research, U.S. Food and Drug Administration. She joined the FDA in 1991, after working at NIAID, NIH since 1979, where she became an expert on retroviruses and endogenous viruses. An important component of Dr. Khan’s current research program in CBER is focused on evaluating adventitious virus detection by next generation sequencing for cell substrate and vaccine safety. Her regulatory responsibilities include review of Investigational New Drugs and Biological License Applications for a variety of candidate vaccines including, influenza and HIV, and novel cell substrates across different product categories. Dr. Khan has been involved in licensure of several viral vaccines and development of various FDA, ICH, PHS, and WHO guidance documents related to cell substrates, vaccines, therapeutics, and xenotransplantation. She is a lead in various working groups on next generation technologies for virus detection, adventitious viruses, and cell substrate safety. Dr. Khan received her Ph.D. in Microbiology from the George Washington University, Washington, D.C.